About Us

Kiniksa Headquarters

About Kiniksa

Kiniksa is a biotech company with an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most.

Passionate employees

Relentless and determined – we put patients at the center of everything we do

Robust pipeline

Product candidates across various stages of development

Focus on immune modulation

Target unmet needs and underserved conditions to deliver life-changing treatment

Strong biologic rationale and validated mechanisms

Furthering our understanding of these therapies through research and development

Potential for multiple indications

Broad applications across multiple therapeutic categories

Management Team

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Sanj K. Patel

CEO & Chairman of the Board

Qasim Rizvi

SVP Operations & CCO

Tom Beetham

EVP Corp Development & Ops, CLO

Mark Ragosa

VP Investor Relations & Finance

Melissa Manno

VP Human Resources

Martina Struck

VP Regulatory Affairs

John Paolini

Chief Medical Officer

Eben Tessari

Chief Business Officer

Mike Megna

VP Finance & Chief Accounting Officer

Dave Nichols

SVP Technical Operations

Dana Martin

SVP Global Medical Affairs

Annalisa D’Andrea

Chief Scientific Officer

Rasmus Holm-Jorgensen

Chief Strategy & Portfolio Officer

previous arrow
next arrow
Slider

Board of Directors

Felix Baker

Lead Director

Sanj K. Patel

Chairman & CEO

Our History

Q3 2020

FDA grants Orphan Drug designation for mavrilimumab for giant cell arteritis

Q3 2020

FDA grants Orphan Drug designation for rilonacept for pericarditis

Q2 2020

Announced that RHAPSODY, a pivotal Phase 3 trial of rilonacept in recurrent pericarditis, met its primary and all major secondary efficacy endpoints

Q2 2020

Announced that 14-day and 28-day data from a treatment protocol of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation in Italy showed earlier and improved clinical outcomes compares to matched contemporaneous controls

Q2 2020

Raised ~$80M in gross proceeds from a follow-on public offering and concurrent private placement

Q2 2020

Announced that the Phase 2a clinical trial of vixarelimab in prurigo nodularis met its primary efficacy endpoint

Q1 2020

Announced early evidence of treatment response with mavrilimumab in 6 patients with severe COVID-19 pneumonia and hyperinflammation

Q4 2019

FDA grants Breakthrough Therapy designation for rilonacept for recurrent pericarditis and final Phase 2 clinical data presented at the American Heart Association 2019 Scientific Sessions.

Q4 2019

Initiated a first-in-human study with antigen challenge TDAR for KPL-404

Q1 2019

Presented rilonacept interim Phase 2 clinical data poster at the American College of Cardiology 68th Annual Scientific Session and raised $88M in gross proceeds from a follow-up public offering and concurrent private placement

Q4 2018

Announced interim Phase 2 results and initiation of pivotal Phase 3 trial for rilonacept; FDA accepted investigational new drug application for mavrilimumab and Kiniksa initiated a global Phase 2 clinical trial for giant cell arteritis

Q3 2018

Presented KPL-716 clinical data at the 27th European Academy of Dermatology and Venereology supporting advancement into chronic pruritic diseases

Q2 2018

Raised $170.7M in gross proceeds from IPO

Q2 2018

Presented initial proof-of-concept data for rilonacept in recurrent pericarditis

Q1 2018

Raised $200M in Series C capital from new and existing investors and completed dosing in the single ascending dose portion of Phase 1a/1b

Q4 2017

Initiated an open-label lead-in study to a planned Phase 3 pivotal trial for KPL-914 in a rare cardiovascular inflammatory disease and acquired the rights to KPL-301

Q3 2017

Acquired the rights to KPL-914 and received an exclusive option to acquire KPL-404

Q2 2017

Raised $40M in Series B capital from new and existing investors and began enrollment in a Phase 1b study in patients with cutaneous inflammatory disease with KPL-716

Q3 2016

Acquired the worldwide rights to our first program (KPL-716) and initiated IND-enabling activities

Q4 2015

Raised $80M in committed Series A capital to focus on rapidly bringing therapies to patients who have unmet need

Q3 2015

Kiniksa is founded in Hamilton, Bermuda, with its US subsidiary headquarters in Massachusetts